The review period for full applications for DEV Funding is currently paused. Applications will re-open in January 2025.
Are you working on groundbreaking therapeutics or vaccine solutions? VITAL invites startups and university-backed projects to apply for non-dilutive funding ranging from $50K to $200K. This funding supports the development, evaluation, or validation of innovative solutions aligned with BARDA’s mission to enhance pandemic preparedness and health security.
The review period for full applications for DEV Funding is currently paused. VITAL expects to resume actively reviewing full applications in March 2025.
Preliminary Applications may be submitted anytime and are assessed on an ongoing basis. If funding becomes available, organizations may be invited to submit a full proposal outside of the standard funding cycle. Otherwise, VITAL will invite select organizations to submit full applications during the next cycle of review (expected January – March 2025). Click HERE to submit a Preliminary Application.
If your organization does not wish to submit a Preliminary Application at this time but would like to be notified by email when VITAL resumes actively reviewing full applications, please click HERE and fill out this form.
Startups and projects will receive project management support and regular mentoring from subject matter experts over the award duration (6 months).
Demonstrate proof-of-concept for high risk, breakthrough technologies and platforms
Advance technologies currently in development to the next milestones and value inflection points
The review period for full applications for DEV Funding is currently paused. Applications will open up in January 2025.
Applications will open up in January 2025. Submit your application by the end of March 2025 to be considered for the next round of review.
We will notify you by in May 2025 if you have been selected to submit a full application for this cycle (by invitation only).
First awards are anticipated to be announced in July 2025.
Preliminary Applications may be submitted anytime and are assessed on an ongoing basis. If funding becomes available, organizations may be invited to submit a full proposal outside of the standard funding cycle. Otherwise, VITAL will invite select organizations to submit full applications during the next cycle of review (expected January – March 2025). Click HERE to submit a Preliminary Application.
If your organization does not wish to submit a Preliminary Application at this time but would like to be notified by email when VITAL resumes actively reviewing full applications, please click HERE and fill out this form.
Watch our info session to gain insights into the VITAL Biotech Accelerator Program and Funding opportunities.
If you or your organization would like to explore collaborations with other potential applicants, please visit our DEV Teaming Page.
Innovative vaccine and therapeutic technologies and platforms aligned with BARDA’s mission.
For more information on BARDA areas of interest, visit https://drive.hhs.gov/partner.html.
BARDA also recently released TPPs relevant to some of its areas of interest: https://medicalcountermeasures.gov/barda/tpp.
We are accepting applications from early-stage biotech companies as well as academic and other innovators globally.
We are accepting applications from early-stage biotech companies as well as academic and other innovators globally. Companies and individuals are welcome to apply for both the Accelerator Program and non-dilutive funding from VITAL. Applications will be reviewed independently. Solicitations for both the Accelerator Program and non-dilutive funding opportunities will be open on an annual basis.
No. SAM.gov registration is not required.
Applications will be evaluated with a particular focus on 1) the ability of the proposed application of the technology to support BARDA’s mission, 2) the uniqueness of the innovation and its ability to address unmet needs, and 3) the capacity for the proposed use of funds to advance the technology to the next value inflection point.
There will be reporting requirements on a quarterly basis, based on milestones achievement, and a final report.
Companies and individuals that receive funding from VITAL will have access to BARDA subject matter experts and other related BARDA resources. Access to these BARDA resources will be managed and coordinated by the VITAL Lead Mentor.
A technology that aligns to the VITAL Hub might also be aligned to some of the other BAN Hubs, including Digital Health and Enabling Technologies. For organizations developing AMR technologies, please also look into BARDA’s Countering Antibiotic-Resistant Bacteria (CARB-X) Program supported by BARDA. Organizations should also look into open Areas of Interest for the BARDA DRIVe EZ-BAA funding opportunity and other BARDA funding and partnership opportunities. The decision about which Hub or program to apply to is up to the organization.
CARB-X: https://carb-x.org/
BARDA DRIVe: https://drive.hhs.gov/partner.html
BARDA BAA funding: https://medicalcountermeasures.gov/barda/barda-baa/
BARDA’s main page: www.medicalcountermeasures.gov
